LENZ Therapeutics Enters Exclusive Licensing Agreement with Arrow Therapeutics to Expand VIZZ Eye Drops Outside the U.S.

Lenz Therapy (NASDAQ(Ticker: LENZ) announced on Wednesday an exclusive licensing and commercialization agreement with Alvotech Pharma Private Limited to expand the international market presence of its newly approved presbyopia eye drop, VIZZ, outside the United States.

Market-Related Views and Data:

The translated content is provided by third-party software.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on public information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making; please refer to actual announcements for authoritative information. For inquiries, please contact: biz@staff.sina.com.cn.

Responsible Editor: Xiaolang Express